Page 64 - பல்கலைக்கழகம் ஆஃப் இல்லினாய்ஸ் சிகாகோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Small Molecules Target Entry Mechanism for Deadly Viruses

Researchers identify a second site on the filovirus to which small drug molecules can bind and prevent infection.

United statesLijun rongUniversity of illinois chicagoCollege of medicineIllinois chicagoஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் ஆஃப் இல்லினாய்ஸ் சிகாகோகல்லூரி ஆஃப் மருந்துஇல்லினாய்ஸ் சிகாகோ

New drug target for Ebola, Marburg viruses - Outbreak News Today

New drug target for Ebola, Marburg viruses - Outbreak News Today
outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesLijun rongUniversity of illinois chicagoCollege of medicineIllinois chicagoஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் ஆஃப் இல்லினாய்ஸ் சிகாகோகல்லூரி ஆஃப் மருந்துஇல்லினாய்ஸ் சிகாகோ

New drug target for Ebola, Marburg viruses

E-Mail IMAGE: UIC s Lijun Rong is part of a team of UIC researchers who have identified a previously unknown site on filoviruses a type of virus, like Ebola, that causes hemorrhagic. view more Credit: Jenny Fontaine/UIC Ebola and Marburg are among the most deadly viruses, with mortality rates from these infections ranging from 25% to 90%. While no drugs currently are available on the market to prevent infection from these viruses they belong to a category of viruses called filoviruses, which are known to cause hemorrhagic fever researchers have identified a few small drug molecules that can block filoviruses from infecting cells by occupying a single site on a glycoprotein in the virus.

United statesBenjamin ramirezLijun rongHyun leeErica ollmann saphireRaghad nowarMichael caffreyLaura cooperRui xiongYangfeng liChan chengAdam schaferGregory thatcherNorton peetLajolla institute of immunologyUniversity of illinois chicago

Researchers develop boosters to train immune responses against Covid-19

February 04, 2021 × The new approach allows a dramatic shortening of the response time upon real infections, which can be critical in certain patients Researchers at the University of Illinois Chicago and California State University in Sacramento, US have found an alternative approach to train immune responses against Covid-19. They have developed a novel strategy that redirects antibodies for other diseases existing in humans to the spike proteins of SARS-CoV-2. The team proposes using peptide-based double-faced “booster” inhibitors, with one face binding to the spike proteins of SARS-CoV-2 and the other face binding to generic hepatitis B antibodies. “Once the SARS-CoV-2 viruses become labelled by the hepatitis B antibodies via intermediate boosters, the viruses will be neutralised,” said Petr Král, UIC Professor of chemistry, physics, pharmaceutical sciences and senior author on the paper.

United statesUniversity of illinois chicagoCalifornia state university in sacramentoIllinois chicagoCalifornia state universityPhysical chemistryஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் ஆஃப் இல்லினாய்ஸ் சிகாகோகலிஃபோர்னியா நிலை பல்கலைக்கழகம் இல் சாக்ரமென்டோஇல்லினாய்ஸ் சிகாகோகலிஃபோர்னியா நிலை பல்கலைக்கழகம்உடல் வேதியியல்

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins The SARS-CoV-2, the new coronavirus behind the current pandemic, infects humans by binding its surface-exposed spike proteins to ACE2 receptors exposed on the cell membranes. Upon a vaccination or a real infection, it takes several weeks before the immunity develops antibodies that can selectively bind to these spike proteins. Such antibody-labeled viruses are neutralized by the natural killer and T cells operated by the human immunity. An alternative approach to train the immunity response is offered by researchers at the University of Illinois Chicago and California State University at Sacramento who have developed a novel strategy that redirects antibodies for other diseases existing in humans to the spike proteins of SARS-CoV-2.

United statesYanxiao hanEmily hendersonCalifornia state university at sacramentoUniversity of illinois chicagoIllinois chicagoCalifornia state universityPhysical chemistry lettersStudy senior authorPharmaceutical sciencesஒன்றுபட்டது மாநிலங்களில்எமிலி ஹென்டர்சன்கலிஃபோர்னியா நிலை பல்கலைக்கழகம் இல் சாக்ரமென்டோபல்கலைக்கழகம் ஆஃப் இல்லினாய்ஸ் சிகாகோஇல்லினாய்ஸ் சிகாகோகலிஃபோர்னியா நிலை பல்கலைக்கழகம்